Bank of New York Mellon Corp trimmed its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 770,903 shares of the biotechnology company’s stock after selling 7,550 shares during the period. Bank of New York Mellon Corp’s holdings in United Therapeutics were worth $114,056,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also made changes to their positions in the company. Quantbot Technologies LP lifted its holdings in United Therapeutics by 537.3% during the 3rd quarter. Quantbot Technologies LP now owns 975 shares of the biotechnology company’s stock worth $114,000 after buying an additional 822 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in United Therapeutics during the 3rd quarter worth about $156,000. SeaCrest Wealth Management LLC purchased a new stake in United Therapeutics during the 4th quarter worth about $178,000. HL Financial Services LLC purchased a new stake in United Therapeutics during the 4th quarter worth about $217,000. Finally, CIBC Asset Management Inc purchased a new stake in United Therapeutics during the 4th quarter worth about $220,000.
A number of brokerages have issued reports on UTHR. ValuEngine downgraded United Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. BidaskClub downgraded United Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday. Credit Suisse Group reaffirmed an “underperform” rating and set a $115.00 price target (down from $120.00) on shares of United Therapeutics in a report on Thursday, February 22nd. Barclays reaffirmed an “underweight” rating and set a $105.00 price target (down from $115.00) on shares of United Therapeutics in a report on Thursday, February 22nd. Finally, TheStreet upgraded United Therapeutics from a “c+” rating to a “b” rating in a research report on Friday, December 15th. Five investment analysts have rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $135.20.
Shares of United Therapeutics Co. (UTHR) opened at $115.96 on Tuesday. The company has a current ratio of 3.26, a quick ratio of 3.01 and a debt-to-equity ratio of 0.12. United Therapeutics Co. has a 52-week low of $112.01 and a 52-week high of $153.58. The company has a market capitalization of $5,010.00, a PE ratio of 10.59 and a beta of 1.26.
United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 21st. The biotechnology company reported $3.89 EPS for the quarter, topping the Zacks’ consensus estimate of $3.59 by $0.30. United Therapeutics had a return on equity of 24.41% and a net margin of 24.22%. The business had revenue of $464.70 million for the quarter, compared to analysts’ expectations of $420.55 million. During the same quarter in the previous year, the firm earned $4.12 earnings per share. The business’s revenue was up 13.6% compared to the same quarter last year. research analysts forecast that United Therapeutics Co. will post 12.48 EPS for the current fiscal year.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.